Gelteq Limited Ordinary Shares(GELS)

Drug Manufacturers - Specialty & Generic · Clayton, VIC

$0.57+0.02 (+3.60%)

Delayed quote: Oct 6, 2026, 2:13 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T18:26:43.621Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:26:43.621Z.

Quote observation: 2026-10-06T18:13:44.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,231,169
TTM revenue · period ending 2025-12-31: N/A

FMP input reference: 6ebeba272bae7de15d59b23151f0025007a9c632b25eeddd13cd9ab927e6ebe5

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GELS PS Ratio Metrics

PS RATIO

N/A

GELS Competitors' PS Ratio

GELS

Gelteq Limited Ordinary Shares

Current

Market Cap

$5.23M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PULM

Pulmatrix, Inc.

vs GELS

Market Cap

$5.24M

PS Ratio

N/A

TTM Avg

1549.76

3Y Avg

519.51

5Y Avg

312.87

LNAI

Lunai Bioworks Inc.

vs GELS

Market Cap

$5.21M

PS Ratio

248.97

TTM Avg

372.81

3Y Avg

372.81

5Y Avg

372.81

INBS

Intelligent Bio Solutions Inc.

vs GELS

Market Cap

$5.24M

PS Ratio

1.24

TTM Avg

1.37

3Y Avg

1.98

5Y Avg

32.27

ALZN

Alzamend Neuro Inc

vs GELS

Market Cap

$5.29M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SNGX

Soligenix, Inc.

vs GELS

Market Cap

$5.34M

PS Ratio

N/A

TTM Avg

41.56

3Y Avg

161.30

5Y Avg

129.34

LIMN

Liminatus Pharma, Inc. Class A Common Stock

vs GELS

Market Cap

$5.12M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs GELS

Market Cap

$5.08M

PS Ratio

N/A

TTM Avg

52.54

3Y Avg

81.05

5Y Avg

85.82

BMGL

Basel Medical Group Ltd Ordinary Shares

vs GELS

Market Cap

$5.03M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs GELS

Market Cap

$4.83M

PS Ratio

24.87

TTM Avg

40.33

3Y Avg

58.43

5Y Avg

54.62

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Gelteq Limited Ordinary Shares (GELS)	$5.23M	N/A	N/A	N/A	N/A
Pulmatrix, Inc. (PULM)vs ›	$5.24M	N/A	1549.76	519.51	312.87
Lunai Bioworks Inc. (LNAI)vs ›	$5.21M	248.97	372.81	372.81	372.81
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.24M	1.24	1.37	1.98	32.27
Alzamend Neuro Inc (ALZN)vs ›	$5.29M	N/A	N/A	N/A	N/A
Soligenix, Inc. (SNGX)vs ›	$5.34M	N/A	41.56	161.30	129.34
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.12M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.08M	N/A	52.54	81.05	85.82
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.03M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.83M	24.87	40.33	58.43	54.62

How this was calculated

The four-quarter calculation detail is unavailable for this stored observation.

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

GELS PS Ratio Metrics

GELS Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics